solo per uso di ricerca

Fedratinib (TG101348) Inibitore di JAK2

N. Cat.: S2736

Fedratinib (SAR302503, TG101348) è un inibitore selettivo di JAK2 con IC50 di 3 nM in saggi senza cellule, 35 e 334 volte più selettivo per JAK2 rispetto a JAK1 e JAK3. Fedratinib inibisce anche FMS-like tyrosine kinase 3 (FLT3) e RET (c-RET) con IC50 di 15 nM e 48 nM, rispettivamente. Fedratinib ha potenziale attività antineoplastica. Fedratinib inibisce la proliferazione e induce l'Apoptosis. Fase 2.
Fedratinib (TG101348) JAK Inibitore Chemical Structure

Struttura chimica

Peso molecolare: 524.68

Vai a

Controllo Qualità (Quality Control)

Lotto: Purezza: 99.99%
99.99

Prodotti spesso usati con Fedratinib (TG101348)

Momelotinib (CYT387)

This compound and Momelotinib are new JAK inhibitors being tested for managing myeloproliferative neoplasms.

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)

Linee cellulari Tipo di saggio Concentrazione Tempo di incubazione Formulazione Descrizione dell'attività PMID
H1975 Apoptosis Assay 0.5-2 μM 12-48 h DMSO induces apoptosis in both dose- and time- dependent manner 25869210
H1650 Apoptosis Assay 0.5-2 μM 12-48 h DMSO induces apoptosis in both dose- and time- dependent manner 25869210
H1975 Function Assay 0.25-1 μM 24 h DMSO inhibits expression of apoptosis-related protein Bcl-XL, Bcl-2, survivin, XIAP 25869210
H1650 Function Assay 0.25-1 μM 24 h DMSO inhibits expression of apoptosis-related protein Bcl-XL, Bcl-2, survivin, XIAP 25869210
H1975 Growth Inhibition Assay 1 μM 48 h DMSO sensitizes cells to the cytotoxicity of erlotinib 25869210
H1650 Growth Inhibition Assay 1 μM 48 h DMSO sensitizes cells to the cytotoxicity of erlotinib 25869210
CD4+ T Function Assay 0.01-1 μM 48 h DMSO reduces the phosphorylation levels of JAK2 and STAT3  25572535
Caco-2  Function Assay 0-120 μM 7 min inhibits thiamine uptake with an IC50 of 2.1 µM 25063672
Caco-2  Function Assay 10/50/100 μM 2 h decreases the flux of [3H]thiamine across the monolayer with IC50 of 6.5 μM 25063672
HEK293 MSR  Function Assay 0-10 μM 7 min inhibits hTHTR2 with an IC50 of 1.2 µM 25063672
MedB-1 Function Assay 1/2 μM 24 h decreases STAT6 phosphorylation concentration dependently 24977668
U2940 Function Assay 1/2 μM 24 h decreases STAT6 phosphorylation concentration dependently 24977668
K1106 Function Assay 1/2 μM 24 h decreases STAT6 phosphorylation concentration dependently 24977668
K562 Growth Inhibition Assay 0-1 μM 72 h inhibits K562 cell proliferation at high concentration 24775308
MDA-MB-468  Growth Inhibition Assay 3 µM 48 h enhanced sibcl6 induced loss of cell viability  24662818
MDA-MB-468 Growth Inhibition Assay 0-4 μM 48 h results significant loss of viability compared to RI-BPI alone 24662818
L428 Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
KMH2 Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
L1236 Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
SUPHD1 Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
HDLM2 Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
K1106P Growth Inhibition Assay 0-5 μM 48 h inhibits cell growth significantly 24610827
L428 Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
KMH2 Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
L1236 Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
SUPHD1 Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
HDLM2 Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
K1106P Apoptosis Assay 0/0.625/1.25 μM 48 h induces the apoptosis  24610827
L428 Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
KMH2 Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
L1236 Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
SUPHD1 Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
HDLM2 Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
K1106P Function Assay 0-5 μM 24 h inhibits JAK2/STAT signaling 24610827
MM.1S  Growth Inhibition Assay IC50=1-3 μM 24584101
TpoR JAK2 WT Growth Inhibition Assay IC50=1.4 (1.3–1.5) μM 24251790
TpoR JAK2 V617F Growth Inhibition Assay IC50=0.8 (0.7–0.9) μM 24251790
TpoR W515L Growth Inhibition Assay IC50=0.8 (0.7–1.0) μM 24251790
Bcr-abl Growth Inhibition Assay IC50=2.7 (2.2–3.3) μM 24251790
JAK2 TW Growth Inhibition Assay IC50=1.8 (1.5–2.3) μM 24251790
JAK2 V617F Growth Inhibition Assay IC50=0.6 (0.6–0.7) μM 24251790
MedB-1 Growth Inhibition Assay 4 μM 24/48/72 h DMSO inhibits cell growth time dependently 23852366
K1106 Growth Inhibition Assay 4 μM 24/48/72 h DMSO inhibits cell growth time dependently 23852366
U2940 Growth Inhibition Assay 4 μM 24/48/72 h DMSO inhibits cell growth time dependently 23852366
FE-PD Growth Inhibition Assay 0.063-4 μM IC50=9.5 μM, inhibits cell growth dose dependently 23372669
HEL Growth Inhibition Assay 0.063-4 μM IC50=1.5 μM, inhibits cell growth dose dependently 23372669
K-562 Growth Inhibition Assay 0.063-4 μM IC50=2.5 μM, inhibits cell growth dose dependently 23372669
L-82 Growth Inhibition Assay 0.063-4 μM IC50=0.98 μM, inhibits cell growth dose dependently 23372669
MAC-1 Growth Inhibition Assay 0.063-4 μM IC50=0.52 μM, inhibits cell growth dose dependently 23372669
MAC-2A Growth Inhibition Assay 0.063-4 μM IC50=0.69 μM, inhibits cell growth dose dependently 23372669
MAC-2B Growth Inhibition Assay 0.063-4 μM IC50=0.54 μM, inhibits cell growth dose dependently 23372669
MY-LA Growth Inhibition Assay 0.063-4 μM IC50=2.1 μM, inhibits cell growth dose dependently 23372669
NC-NC Growth Inhibition Assay 0.063-4 μM IC50=1.0 μM, inhibits cell growth dose dependently 23372669
SE-AX Growth Inhibition Assay 0.063-4 μM IC50=1.5 μM, inhibits cell growth dose dependently 23372669
SR-786 Growth Inhibition Assay 0.063-4 μM IC50=4.6 μM, inhibits cell growth dose dependently 23372669
M-MOK  Growth Inhibition Assay 25 µM  24/48/72 h DMSO inhibits cell growth time dependently 21853157
HEL Growth Inhibition Assay IC50=305 nM 18394554
Ba/F3 JAK2V617F Growth Inhibition Assay IC50=270 nM 18394554
MV4-11 Antiproliferative assay 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs by celltiter-blue assay, EC50 = 0.079 μM. 28280261
MM1S Antiproliferative assay 72 hrs Antiproliferative activity against human MM1S cells after 72 hrs by trypan blue exclusion assay, IC50 = 1 μM. 28280261
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
Clicca per visualizzare più dati sperimentali sulle linee cellulari

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Peso molecolare 524.68 Formula

C27H36N6O3S

Conservazione (Dalla data di ricezione)
N. CAS 936091-26-8 Scarica SDF Conservazione delle soluzioni stock

Sinonimi SAR302503 Smiles CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4

Solubilità (Solubility)

In vitro
Lotto:

DMSO : 100 mg/mL (190.59 mM)
(Il DMSO contaminato da umidità può ridurre la solubilità. Utilizzare DMSO fresco e anidro.)

Water : Insoluble

Ethanol : Insoluble

Calcolatore di Molarità

Massa Concentrazione Volume Peso molecolare
Calcolatore di Diluizione Calcolatore del Peso Molecolare

In vivo
Lotto:

Calcolatore di formulazione in vivo (Soluzione chiara)

Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)

mg/kg g μL

Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Risultati del calcolo:

Concentrazione di lavoro: mg/ml;

Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.

Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.

Meccanismo d'azione (Mechanism of Action)

Targets/IC50/Ki
JAK2
(Cell-free assay)
3 nM
JAK2 (V617F)
(Cell-free assay)
3 nM
FLT3
(Cell-free assay)
15 nM
RET
(Cell-free assay)
48 nM
In vitro

Fedratinib (TG101348) significantly inhibits JAK2 V617F, Flt3, and Ret with IC50 of 3 nM, 15 nM, and 48 nM, respectively. This compound has an IC50 ~300-fold higher for the closely related JAK3 and is a less potent inhibitor of the JAK1 and TYK2 family members. It inhibits proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with IC50 of 305 nM and 270 nM, respectively. TG-101348 also inhibits proliferation of parental Ba/F3 cells to a comparable level, with IC50 of ~420 nM. Its treatment reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. It does not show proapoptotic activity in control normal human dermal fibroblasts at concentrations up to 10 μM, and the antiproliferative IC50 against fibroblasts is >5 μM. This compound treatment decreases GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibits STAT5 as well as GATA S310 phosphorylation. TG101348 inhibits the proliferation of HMC-1.1 (KITV560G) cells, with somewhat lower potency than HMC-1.2 (KITD816V, KITV560G) cells, with IC50 of 740 nM and 407 nM, respectively.

Saggio chinasico
Saggi di attività chinasica senza cellule
I valori di IC50 di Fedratinib (TG101348) sono determinati commercialmente utilizzando il servizio di profilazione delle chinasi InVitrogen per uno screening di 223 chinasi che includeva JAK2 e JAK2V617F o Carna Biosciences per lo screening di tutti i membri della famiglia Janus chinasi, inclusi JAK1 e Tyk2. La concentrazione di ATP è impostata approssimativamente al valore Km per ciascuna chinasi.
In vivo

Fedratinib (TG101348) has potential for efficacious treatment of JAK2V617F-associated myeloproliferative diseases (MPD). In treated animals, there is a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis, correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction. There are no apparent toxicities and no effect on T cell number. Oral administration of this compound (120 mg/kg) significantly inhibits PV progenitor erythroid differentiation in vivo.

Riferimenti

Applicazioni (Applications)

Metodi Biomarcatori Immagini PMID
Western blot p-JAK2 / p-STAT1 / p-STAT3 / p-STAT6 / p-STAT5 / JAK2 c-Myc / PIM1
S2736-WB1
24610827
Growth inhibition assay Cell proliferation
S2736-viability1
24610827

Informazioni sullo studio clinico (Clinical Trial Information)

(dati da https://clinicaltrials.gov, aggiornato il 2026-07-29)

Numero NCT Reclutamento Condizioni Sponsor/Collaboratori Data di inizio Fasi
NCT07734077 NOT_YET_RECRUITING
Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
John Mascarenhas
2026-12-01 PHASE1; PHASE2
NCT04817007 ACTIVE_NOT_RECRUITING
Myelofibrosis
Bristol-Myers Squibb
2021-03-22 PHASE1; PHASE2
NCT04282187 RECRUITING
Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis
University of Washington
2020-03-24 PHASE2
NCT05393674 COMPLETED
Primary Myelofibrosis; Secondary Myelofibrosis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2022-06-14 PHASE2
NCT05177211 COMPLETED
Myeloproliferative Neoplasm; Chronic Neutrophilic Leukemia; MDS
H. Lee Moffitt Cancer Center and Research Institute
2022-03-01 PHASE2
NCT05127174 TERMINATED
Myeloproliferative Neoplasm
H. Lee Moffitt Cancer Center and Research Institute
2022-03-14 PHASE1